Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2006 1
2007 2
2008 3
2009 4
2010 2
2011 1
2015 1
2016 1
2017 1
2018 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study.
Urowitz MB, Isenberg DA, Wallace DJ. Urowitz MB, et al. Lupus Sci Med. 2015 Aug 11;2(1):e000104. doi: 10.1136/lupus-2015-000104. eCollection 2015. Lupus Sci Med. 2015. PMID: 26301100 Free PMC article.
OBJECTIVE: To evaluate the safety and efficacy of hCDR1 (Edratide) in patients with systemic lupus erythematosus (SLE). METHODS: Patients (n=340) with SLE 4 ACR criteria (4-11, mean 7) with active disease (SLEDAI-2K of 6-12). ...The secondary predefined endpoint, BILAG, wa …
OBJECTIVE: To evaluate the safety and efficacy of hCDR1 (Edratide) in patients with systemic lupus erythematosus (SLE). METHODS: Pati …
[New therapeutic targets].
Calvo Alén J. Calvo Alén J. Reumatol Clin. 2008 Mar;4 Suppl 1:35-9. doi: 10.1016/S1699-258X(08)76138-2. Epub 2009 Feb 3. Reumatol Clin. 2008. PMID: 21794552 Free article. Spanish.
In this sense, SLE is the disease for which most trials are being carried out, including treatment with agents such as sodic abetimus (LJP 394) a synthetic analog of DNA, edratide (TV4710) a peptide from the antigen-binding site of anti-double stranded DNA, or monoclonal a …
In this sense, SLE is the disease for which most trials are being carried out, including treatment with agents such as sodic abetimus (LJP 3 …
Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
Sthoeger ZM, Sharabi A, Molad Y, Asher I, Zinger H, Dayan M, Mozes E. Sthoeger ZM, et al. J Autoimmun. 2009 Aug;33(1):77-82. doi: 10.1016/j.jaut.2009.03.009. Epub 2009 Apr 5. J Autoimmun. 2009. PMID: 19346102
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by dysregulation of cytokines, apoptosis, and B- and T-cell functions. The tolerogenic peptide, hCDR1 (Edratide), ameliorated the clinical manifestations of murine lupus via down-regulation of pro-i …
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by dysregulation of cytokines, apoptosis, and B- and T-cell funct …
Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations.
Elmann A, Sharabi A, Dayan M, Zinger H, Ophir R, Mozes E. Elmann A, et al. Arthritis Rheum. 2007 Jul;56(7):2371-81. doi: 10.1002/art.22736. Arthritis Rheum. 2007. PMID: 17599765 Free article.
OBJECTIVE: To identify genes that are differently expressed in (NZB x NZW)F(1) mice with established lupus compared with healthy controls, and to determine how gene expression is affected by treatment with hCDR1 (Edratide), a peptide synthesized on the basis of the sequenc …
OBJECTIVE: To identify genes that are differently expressed in (NZB x NZW)F(1) mice with established lupus compared with healthy controls, a …
[Systemic lupus erythematosus: future therapeutic avenues].
Amoura Z, Haroche J, Piette JC. Amoura Z, et al. Rev Med Interne. 2008 Sep;29(9):718-24. doi: 10.1016/j.revmed.2008.02.013. Epub 2008 Jul 10. Rev Med Interne. 2008. PMID: 18619716 French.
These new therapies are: (1) "B lymphocyte (BL)" inhibitors such as anti-CD20 monoclonal antibody, anti-CD22 monoclonal antibody, BlyS antagonists, tolerogens of pathogenic-antibody secreting LB (LJP 394) and edratide; (2) "Inhibitors of the costimulation" between antigen- …
These new therapies are: (1) "B lymphocyte (BL)" inhibitors such as anti-CD20 monoclonal antibody, anti-CD22 monoclonal antibody, BlyS antag …
The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model.
Sharabi A, Luger D, Ben-David H, Dayan M, Zinger H, Mozes E. Sharabi A, et al. J Immunol. 2007 Oct 15;179(8):4979-87. doi: 10.4049/jimmunol.179.8.4979. J Immunol. 2007. PMID: 17911582
Experimental systemic lupus erythematosus (SLE) can be induced in mice following immunization with an anti-DNA mAb expressing a major Id, 16/6Id. Treatment with a peptide, designated human CDR1 (hCDR1; Edratide), that is based on the sequence of CDR1 of the 16/6Id ameliora …
Experimental systemic lupus erythematosus (SLE) can be induced in mice following immunization with an anti-DNA mAb expressing a major Id, 16 …
17 results